Found: 16
Select item for more details and to access through your institution.
Association between Early Venous Thromboembolism Prophylaxis, Bleeding Risk, and Venous Thromboembolism among Critically Ill Patients with Thrombocytopenia.
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
Scoping Review of Pulmonary Telemedicine Consults: Current Knowledge and Research Gaps.
- Published in:
- Annals of the American Thoracic Society, 2023, v. 20, n. 3, p. 456, doi. 10.1513/AnnalsATS.202205-404OC
- By:
- Publication type:
- Article
Variable Monitoring of Veterans with Group 3 Pulmonary Hypertension Treated with Off-Label Pulmonary Vasodilator Therapy.
- Published in:
- 2022
- By:
- Publication type:
- Letter
How Closely Do Clinical Trial Participants Resemble "Real-World" Patients with Groups 2 and 3 Pulmonary Hypertension? A Structured Review.
- Published in:
- 2020
- By:
- Publication type:
- research
Organization of pulmonary hypertension care in non‐expert care settings: Lessons learned from a multi‐site study.
- Published in:
- Health Services Research, 2023, v. 58, n. 3, p. 663, doi. 10.1111/1475-6773.14114
- By:
- Publication type:
- Article
Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension.
- Published in:
- Lung, 2023, v. 201, n. 6, p. 565, doi. 10.1007/s00408-023-00646-2
- By:
- Publication type:
- Article
A Multimodal Prediction Model for Diagnosing Pulmonary Hypertension in Systemic Sclerosis.
- Published in:
- Arthritis Care & Research, 2023, v. 75, n. 7, p. 1462, doi. 10.1002/acr.24969
- By:
- Publication type:
- Article
Correction to: Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis‑Related Pulmonary Hypertension.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension.
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 3, p. 651, doi. 10.1007/s10557-022-07420-1
- By:
- Publication type:
- Article
Cluster analysis identifies novel real-world lung disease– pulmonary hypertension subphenotypes: implications for treatment response.
- Published in:
- ERJ Open Research, 2024, v. 10, n. 3, p. 1, doi. 10.1183/23120541.00959-2023
- By:
- Publication type:
- Article
Multisystem Healthcare Use among U.S. Veterans with Pulmonary Hypertension.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Real‐world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real‐world Evidence Working Group.
- Published in:
- Pulmonary Circulation, 2023, v. 13, n. 4, p. 1, doi. 10.1002/pul2.12317
- By:
- Publication type:
- Article
Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity.
- Published in:
- Pulmonary Circulation, 2022, v. 12, n. 4, p. 1, doi. 10.1002/pul2.12117
- By:
- Publication type:
- Article
Socioeconomically disadvantaged veterans experience treatment delays for pulmonary arterial hypertension.
- Published in:
- Pulmonary Circulation, 2022, v. 12, n. 4, p. 1, doi. 10.1002/pul2.12171
- By:
- Publication type:
- Article
Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease.
- Published in:
- Pulmonary Circulation, 2021, v. 11, n. 2, p. 1, doi. 10.1177/20458940211001714
- By:
- Publication type:
- Article